Andexxa® (coagulation factor Xa [recombinant], inactivated-zhzo) – New orphan drug approval
May 4, 2018 - Portola Pharmaceuticals announced the FDA approval of Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], for patients treated with Xarelto® (rivaroxaban) and Eliquis® (apixaban), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Top